Retrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers.
نویسندگان
چکیده
BACKGROUND We hypothesize that the combination of an mTOR inhibitor, sirolimus, with a well-known cytotoxic agent, cyclophosphamide, provides a well-tolerated and promising alternative treatment for advanced, differentiated thyroid cancers (DTC). METHODS This retrospective review extracted data from patients treated for advanced DTC at the University of Michigan Comprehensive Cancer Center from 1995 through 2013. Fifteen patients treated with combination sirolimus and cyclophosphamide were identified as the sirolimus+cyp group. Seventeen patients treated with standard of care and enrolled in clinical trials were identified as the comparison group. RESULTS The one-year progression free survival rate (PFS) was 0.45, 95% CI [0.26, 0.80] in the sirolimus+cyp population and 0.30, 95% CI [0.13, 0.67] in the comparison population. The hazard ratio for PFS from initiation of treatment was 1.47, 95% CI [0.57, and 3.78]. In patients treated as first line, one-year PFS rate was 0.57, 95% CI [0.30, 1.00] in the sirolimus+cyp group and relatively unchanged at 0.29, 95% CI [0.11, 0.74] in the comparison group. The hazard ratio for PFS for first line patients was 1.10, 95% CI[ 0.4, and 3.5]. In patients with 3 or fewer sites of metastases, the one year PFS was 0.58, 95% CI [0.33, 1.00] in the sirolimus+cyp group, and 0.37, 95% CI [0.17, 0.80] in the comparison group. The average number of toxicities was 0.87 in the sirolimus+cyp patients and 1.71 in the comparison group. CONCLUSIONS The combination of sirolimus and cyclophosphamide was generally well tolerated with similar progression free survival, highlighting its applicability in patients with limited options.
منابع مشابه
Evaluation of response to I-131 ablative therapy in patients with differentiated thyroid carcinoma: A five year retrospective study [Persian]
Differentiated thyroid carcinomas usually show good uptake and response to I-131 ablative treatment. In this study, 90 patients following near total thyroidectomy who were referred to our institute for I-131 therapy are retrospectively studied. The patients are divided in two groups. Group 1 revealed complete ablation after one dose of I-131. Group 2 needed more than one dose of I-131 for...
متن کاملEvaluation of the Differentiated Thyroid Cancer and the Results of the 131 Administration
Differentiated thyroid cancers (follicular and papillary) are in the group of the cancers with relatively good prognosis and most of them have tendency to absorb the Iodine, so the 131 is used for tlie ablation of the thyroid tissue, rest of the tumor and metastases. This study revealed that for this purpose most of the Iranian's patients (more than 70%)have been hospitalized more than once and...
متن کاملThyroid hormone replacement one day before 131I therapy in patients with well-differentiated thyroid cancer
Objective: The current study aimed to determine the efficacy of radioiodine-131 (131I) ablation therapy with thyroid hormone replacement one day before 131I administration in patients with well-differentiated thyroid cancer (DTC). Methods: This retrospective study included 29 patients who underwent 131I therapies twice for DTC during 6-12 months. Since all the patients obviously had residual l...
متن کاملExtremity Radioactive Iodine Uptake on Post-therapeutic Whole Body Scan in Patients with Differentiated Thyroid Cancer
Objective(s): We investigated a frequency of lower extremity uptake on the radioactive iodine (RAI) whole body scan (WBS) after RAI treatment in patients with differentiated thyroid cancer, in order to retrospectively examine whether or not the frequency was pathological. Methods: This retrospective study included 170 patients with thyroid cancer, undergoing RAI treatment. Overall, 99r (58%) an...
متن کاملخصوصیات دموگرافیک و ریسک فاکتورها در 320 مورد کانسر تیروئید
Background: Thyroid cancer is a rare disease which includes less than 1% percent of all human cancers. The aim of this study is to evaluate the demographic characteristics and risk factors among patients with thyroid malignancy at the Cancer institute and Imam Khomeini hospital in Tehran Iran. Methods: This is a retrospective descriptive study of the charts of 320 patients admitted with t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of thyroid disorders & therapy
دوره 4 3 شماره
صفحات -
تاریخ انتشار 2015